KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Liabilities and Shareholders Equity (2016 - 2025)

Biomarin Pharmaceutical's Liabilities and Shareholders Equity history spans 17 years, with the latest figure at $7.6 billion for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 8.66% year-over-year to $7.6 billion, compared with a TTM value of $29.8 billion through Dec 2025, up 7.32%, and an annual FY2025 reading of $7.6 billion, up 8.66% over the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $7.6 billion at Biomarin Pharmaceutical, roughly flat from $7.6 billion in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $7.6 billion in Q3 2025, with the low at $5.8 billion in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $6.6 billion, with a median of $6.7 billion recorded in 2023.
  • Biggest YoY gain for Liabilities and Shareholders Equity was 22.91% in 2021; the steepest drop was 2.93% in 2021.
  • Tracing BMRN's Liabilities and Shareholders Equity over 5 years: stood at $6.0 billion in 2021, then rose by 6.17% to $6.4 billion in 2022, then increased by 7.32% to $6.8 billion in 2023, then rose by 2.15% to $7.0 billion in 2024, then increased by 8.66% to $7.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Liabilities and Shareholders Equity are $7.6 billion (Q4 2025), $7.6 billion (Q3 2025), and $7.5 billion (Q2 2025).